According to ICMR-NIV study, Covaxin Effective against Brazil Variant
ICMR-NIV study reported that Covaxin (Indian-made vaccine) is effective against the Brazil variant of COVID-19
The COVID-19 pandemic has destructed many life and properties worldwide, but the good news is not behind. ICMR-NIV study reported that Covaxin (Indian-made vaccine) is effective against the Brazil variant of COVID-19. Firstly it was also reported that Covaxin is also effective against the double mutant of COVID-19. Presently in India, two vaccines are approved by the government, Covaxin (Bharat Biotech) and Covishield (Serum Institute of India), to provide vaccination across the country.
Covaxin is effective against the Brazil variant, according to a new study published in bioRxiv preprint on April 30. When compared to natural infection, the two-dose regimen substantially increased IgG antibody titer and neutralizing efficacy against the Brazil variant and D614G variant.
The 19 convalescent sera specimens collected from recovered cases of Covid-19 were tested for IgG immune response and neutralizing activity, and validated for UK (B.1.1.7), South African (B.1.351), and Brazilian (B.1.1.28.2) forms. Cases of SARS-CoV-2 UK variant infection have been registered in India (B.1.1.7). In foreign travelers, the South African variant (B.1.351) and the Brazilian variant P2 lineage (B.1.1.28.2) have recently been discovered.
The effect of the introduction of these new variants on the effectiveness of currently available Covid-19 vaccines or the neutralizing potential of sera from people who were naturally infected with the previously circulating strains is currently being investigated.
